Novo Nordisk partners with Hims & Hers to expand U.S. access to FDA-approved semaglutide therapies, including Ozempic and Wegovy, while the telehealth platform ends promotion of compounded GLP-1 drugs following FDA scrutiny
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
Novo Nordisk has announced a new agreement with telehealth platform Hims & Hers aimed at expanding patient access to its FDA-approved semaglutide medicines in the United States. The agreement, which will take effect later this month, will allow patients using the telehealth service to obtain branded therapies including Ozempic and Wegovy at self-pay prices similar to those offered by other telehealth providers.
Under the terms of the partnership, Hims & Hers will offer access to Ozempic injections at doses of 0.5 mg, 1 mg, and 2 mg, as well as Wegovy in both injectable and oral tablet formulations. Injectable Wegovy will be available in doses ranging from 0.25 mg to 2.4 mg, while oral semaglutide tablets will be offered at doses including 1.5 mg, 4 mg, 9 mg, and 25 mg.
As part of the agreement, Hims & Hers will discontinue advertising compounded GLP-1 medicines on its platform and in marketing materials. Existing patients who are currently using compounded GLP-1 therapies through the service will have the option to transition to FDA-approved treatments when clinically appropriate, following consultation with a healthcare professional.
Mike Doustdar, President and CEO of Novo Nordisk, said the partnership represents an important step toward improving patient access to clinically validated obesity and diabetes treatments. He emphasized that Wegovy is not only an obesity therapy but also a treatment shown to reduce the risk of cardiovascular events such as heart attack and stroke in adults with obesity and established heart disease.
The agreement further expands access to Novo Nordisk’s semaglutide portfolio through digital care platforms. These products are already broadly available in the United States through more than 70,000 pharmacies, Novo Nordisk’s direct-to-consumer NovoCare Pharmacy service and selected digital health platforms.
The agreement follows a series of developments over the past few months involving Novo Nordisk and Hims & Hers related to compounded GLP-1 medicines.
In February 2026, Novo Nordisk filed a patent infringement lawsuit against the telehealth company after it launched a low-cost compounded version of the Wegovy pill. The move drew regulatory scrutiny, with the U.S. Food and Drug Administration warning it would take enforcement action against companies’ mass-marketing non-FDA-approved compounded GLP-1 drugs, citing concerns over safety, quality, and misleading promotion.
Following the regulatory pressure, Hims & Hers withdrew its compounded semaglutide offering and halted promotion of products.
The newly announced collaboration effectively resolves the dispute, with Novo Nordisk dropping the lawsuit while Hims & Hers shifts its weight-loss business toward offering only FDA-approved branded semaglutide therapies through its telehealth platform.
Results from the phase 3 OASIS-4 trial showed that once-daily oral semaglutide 25 mg led to an average weight loss of 16.6% over 64 weeks, compared with 2.7% with placebo, when used alongside diet and exercise. The therapy also enabled 76% of patients to achieve at least 5% body-weight reduction, with gastrointestinal events such as nausea, diarrhea, and vomiting reported as the most common adverse effects.
Reference
Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model, 09 March 2026, News Details
About Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.